Detailed Description:~The trial is a non-inferiority trial; patients, depending on intra-operative or post-operative sentinel lymph node assessment, are randomly assigned to one of the two intervention groups:~group 1: removal of I-II level of axillary lymph nodes (standard treatment). Removal of at least 10 lymph nodes is recommended.~group 2: no axillary lymph nodes dissection (experimental treatment). Patients for whom sentinel lymph node cannot be found, will undergo complete dissection of the axillary cavity as required by international guidelines.~After surgery, according to their bio-pathological profile and to the international guidelines criteria, patients will be able to receive:~no further treatment~complementary radiotherapy~adjuvant medical therapy (chemo and / or hormone therapy).~Patients will be checked for at least 5 years in the following ways:~six-monthly clinical examination for the first 5 years and yearly thereafter~mammography + annual breast ultrasound~annual axillary ultrasound in cases not subjected to dissection.
Italian Multicentric non inferiority two-arm randomized clinical trial to verify that the experimental treatment (omission of axillary lymph node intervention) in the presence of sentinel lymph node metastases does not lead to a significant worsening in survival or in the risk of locoregional recurrence compared to standard treatment (removal of I-II level of axillary lymph nodes).